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2011 was a blockbuster year for the stem cell field. Researchers made great progress in growing
complex organs in vitro and producing a variety of cell types on demand. But in the last fewmonths,
a few studies have markedly propelled the field forward. This Select highlights these recent discov-
eries, including the first embryonic stem cells (ESCs) made by nuclear transfer, a new type of adult
stem cell, and dopamine neurons that reverse symptoms of a neurodegenerative disease.Illustration of an individual with Parkin-
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Parkinson’s disease results from the death of dopamine neurons in a region of themidbrain
involved in movement, which leads to tremors, stiffness, and difficulty walking. Current
therapies for Parkinson’s disease are severely limited, and thus, researchers have aggres-
sively sought alternative approaches, such as stem cell therapies. Previous studies have
generated dopamine neurons from human pluripotent stem cells (PSCs), but these
neurons perform poorly in transplantation experiments: they fail to engraft, display neural
overgrowth, or differentiate inappropriately into nondopaminergic neurons. Now, Kriks
et al. (2011) develop a new strategy for making dopamine neurons from human ESCs;
these neurons efficiently integrate into the brains of monkeys and improve motor function
of mouse and rat models of Parkinson’s disease.
Dopamine neurons originate from a group of cells in the developing brain, called floor-
plate neurons. Recently, the Studer lab reported a protocol for generating precursors of
floor-plate cells from human ESCs. When they treat these precursor cells with a specific
cocktail of factors (i.e., Sonic Hedgehog activators, canonical WNT activators, and
SMAD inhibitors), the neurons express genes that are characteristics of dopamine
neurons. The cells also display electrophysiological properties distinct to dopamine
neurons of the midbrain. Next, Kriks et al. inject the induced neurons into the brains of
mice and rats with lesions in their midbrain dopamine neurons (which mimics Parkinson’s
disease). The transplanted cells survive for at least 5 months in both animal models, andthey reverse some of the motor disabilities caused by the brain damage. Kriks and colleagues then scale up the production of the
dopamine neurons 100-fold and transplant the cells into two rhesus monkeys with Parkinsonian-like symptoms. The neurons
successfully integrate into the host after 1 month, but future experiments are needed to determine whether the transplanted cells
can recover the monkeys’ motor function and what the long-term effects of the cell therapy will have.
Kriks, S., et al. (2011). Nature 480, 547–551.Human neurons (red) differentiate from iPSCs
derived from a patient with Timothy syndrome.
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Kriks and colleagues take a significant stride toward developing a cell replace-
ment therapy for Parkinson’s disease, but these types of treatments still remain
quite far from the clinic. In themeantime, reprogramming technologies are having
amore immediate impact in another arena: diseasemodeling and drug discovery
for neuropsychiatric disorders. Now, a new study by Pasxca et al. elegantly
demonstrates this strategy for Timothy syndrome.
Timothy syndrome is caused by a missense mutation in the CACNA1C gene,
which encodes a subunit of the calcium channel Cav1.2. This mutation alters
the electrophysiological properties of the channel, leading to cardiac arrhythmia,
delays in neurodevelopment, and autism spectrum disorders. Pasxca et al. take
fibroblast skin cells from two individuals with Timothy syndrome and three
controls. They convert the fibroblasts to induced pluripotent stem cells (iPSCs)
by standard reprogramming techniques (i.e., they infect the cells with retrovi-
ruses expressing SOX2, OCT3/4, KLF4, and C-MYC). They then coax the cells
into forming neurons. The Timothy syndrome neurons display dramatic changes
in calcium signaling compared to the control neurons. But, more surprisingly,
they also show abnormal expression of tyrosine hydroxylase, an enzyme critical
for making the key neurotransmitters dopamine and norepinephrine. Pasxca and
colleagues then engineer a mouse model of Timothy syndrome. Although the
animals display some of the phenotypes observed in the human neurons, the
animals don’t generate neurons that overproduce dopamine and norepinephrine. Finally, Pasxca and colleagues use the Timothy
syndrome neurons as a drug testing ground. They identify a new class of compounds that reduces the extra dopamine-producingCell 148, January 20, 2012 ª2012 Elsevier Inc. 9
neurons by 70%. Such results highlight the importance of studying human neurons from patients—an approach made immensely
more accessible by advances in reprogramming technologies.
Pasxca, S.P., et al. (2011). Nat. Med. 17, 1657–1662.A human blastocyst obtained after transfer of a
skin cell genome into a human oocyte. The green
fluorescence originates from the skin cell genome.
The bright cluster of cells in the center is the inner
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Pasxca et al. reprogram skin cells by overexpressing four master transcription
factors linked to pluripotency, but this isn’t the only approach for converting
differentiated cells into stem cells. In many animals, ‘‘personalized’’ stem
cells can be made through a technique called ‘‘somatic cell nuclear transfer.’’
Specifically, a diploid genome from a differentiated cell is injected into an oocyte,
and the oocyte’s haploid genome is removed. When this ‘‘fertilized’’ egg starts to
develop, stem cells can be harvested from the blastocyst. Now, Noggle et al.
(2011) report the first human ESC lines derived from somatic cell nuclear transfer.
But there’s one hitch: the cells have three copies of the genome.
Noggle et al. begin by switching out the oocyte genome with that from
a fibroblast cell at metaphase II of meiosis because this strategy has been
successful in other mammalian species. However, the human zygote stops
dividing after only a few rounds of mitosis (i.e., with only six to ten cells). A series
of control experiments suggest that the oocyte genome is required to initiate
active transcription from the transplanted genome; as transcription fails, the
zygote stops dividing. When the oocyte genome is kept after the fibroblast
nucleus is injected,20%of the zygotes develop to the blastocyst stage. Noggle
and colleagues then derive two stem cell lines from these embryos. Although the
cells are triploid, they are still pluripotent (i.e., they can give rise to all three germ
layers). Most impressively, the nuclear transfer method appears highly efficient at
removing the epigenetic memory of the fibroblast cell, possibly more so than the
standard reprogramming method via forced expression of transcription factors.
Many obstacles—both technical and political—still remain before this technique
catches up to the standard reprogramming method. Nevertheless, this study
takes a major stride toward reaching the paramount goal of producing a reprog-
rammed stem cell that is indistinguishable from ‘‘natural’’ ESCs.
Noggle, S., et al. (2011). Nature 478, 70–75.RPE cells form a pigmented layer of the human retina, which is required
to keep the rods and cones healthy. Image from Salero et al. (2012).The Eye’s Secret Stem Cells
2011was also a big year for research on adult stem cells. Like
embryonic stem cells, adult stem cells have the ability to self-
renew, but they typically can give rise to only a few different
types of cells. In addition, adult stem cells reside in organs
throughout the lifetime of an animal, where they repair and
regenerate tissues. Adult stem cells have been identified in
a handful of organs, such as the skin, gut, and brain, but for
many tissues, these repair factories still await discovery.
Now, Salero et al. (2012) discover a new population of adult
stem cells in the human eye, specifically in the retinal pigment
epithelial (RPE) cells.
RPE cells form a layer in the retina that helps keep the rods and cones healthy. Degeneration of RPEs is the leading cause of age-
related vision loss. In some amphibians, damage to the retina triggers RPE cells to proliferate and regenerate numerous parts of the
retina, including the lens and neurons. To search for similar cells in humans, Salero et al. isolate single RPE cells from human donors
and culture them with serum. Most of the cells don’t divide or produce only a few progeny, but 10% of the clones display strong
self-renewal properties; they form stem cell-like spheres that can be serially propagated. These self-renewing RPE cells are also
multipotent. They can differentiate into cells derived from both the neuroectoderm lineage (i.e., a neuron phenotype) and the
mesoderm lineage (i.e., adipocyte, osteogenic, and chondrocyte phenotypes), which is quite rare for a cell derived from the CNS.
More experiments are needed to characterize the full differentiation capacity of the RPE stem cells, but clearly, these cells offer a
valuable new resource for modeling RPE-related diseases and developing treatments for age-related blindness.
Salero, E., et al. (2012). Cell Stem Cell 10, 88–95.
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